Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Allovir Inc is a biotechnology business based in the US. Allovir Inc shares (ALVR) are listed on the NASDAQ and all prices are listed in US Dollars. Allovir Inc employs 107 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $7.85 |
|---|---|
| 52-week range | $3.17 - $26.41 |
| 50-day moving average | $7.01 |
| 200-day moving average | $7.34 |
| Wall St. target price | $26.25 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.92 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.85 from 2022-09-29
| 1 week (2022-09-23) | 6.22% |
|---|---|
| 1 month (2022-09-01) | 4.67% |
| 3 months (2022-07-01) | 90.07% |
| 6 months (2022-04-01) | 13.77% |
| 1 year (2021-10-01) | -69.80% |
|---|---|
| 2 years (2020-10-01) | -71.93% |
| 3 years (2019-09-27) | N/A |
| 5 years (2017-09-27) | N/A |
| Gross profit TTM | $165,000 |
|---|---|
| Return on assets TTM | -44.81% |
| Return on equity TTM | -83.35% |
| Profit margin | 0% |
| Book value | $2.51 |
| Market capitalisation | $687.7 million |
TTM: trailing 12 months
We're not expecting Allovir Inc to pay a dividend over the next 12 months.
Over the last 12 months, Allovir Inc's shares have ranged in value from as little as $3.17 up to $26.41. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Allovir Inc's is 1.0016. This would suggest that Allovir Inc's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Allovir, Inc. , a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019.
Our list of 10 dividend stocks to watch in 2022.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.